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Abstract  
Natural antibodies (nAbs) are most commonly defined as immunoglobulins present in the 
absence of pathological conditions or deliberate immunizations. Occurrence of nAbs in germ- 
and antigen-free mice, suggest that their production is driven, at least in part, by self-antigens. 
Accordingly, nAbs are constituted of natural autoantibodies (nAAbs), and can belong to the IgM, 
IgG or IgA subclasses. These nAbs provide immediate protection against infection while the 
adaptive arm of the immune system mounts a specific and long-term response. Beyond 
immediate protection from infection, nAbs have been shown to play various functional roles in 
the immune system, which include clearance of apoptotic debris, suppression of autoimmune and 
inflammatory responses, regulation of B cell responses, selection of the B cell repertoire, and 
regulation of B cell development. These various functions of nAbs are afforded by their 
reactivity, which is broad, cross-reactive, and shown to recognize evolutionarily fixed epitopes 
shared between foreign and self-antigens. Furthermore, nAbs have unique characteristics that 
also contribute to their functional roles and set them apart from antigen-specific antibodies. In 
further support for the role of nAbs in the protection against infections and in the maintenance of 
immune homeostasis, the therapeutic preparation of polyclonal immunoglobulins, intravenous 
immunoglobulin (IVIG), rich in nAbs is commonly used in the replacement therapy of primary 
and secondary immunodeficiencies and in the immunotherapy of a large number of autoimmune 
and inflammatory diseases. Here we review several topics on nAbs features and functions, and 
therapeutic applications in human diseases. 
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Introduction 
The successful treatment of diphtheria using immune serum by Emil Adolf von Behring and 
Émile Roux in the 19th century paved the way for discovery of antibodies in serum as gamma 
globulin proteins, and its basic structure was elucidated in the 20th century [1, 2]. There was a 
parallel expansion in the application of serum with anti-infection capabilities against other 
microbial diseases to confer immunity against dreadful pathogens, hence the name 
immunoglobulins (Igs) came into practice. Subsequently, thorough characterization of the 
antibodies produced following microbial infection or immunization, referred to as immune 
antibodies, was done [3]. Further studies identified varieties of Igs differing in their structure and 
function. These are divided into five classes/isotypes, namely IgG, IgM, IgA, IgE, and IgD [4]. 
Antibody production is the main function of differentiated B cells. Well established as effector 
molecules of the adaptive compartment, Abs also participate as links or organizing factors for 
certain functions of the innate immune system by identifying and neutralizing the pathogens in 
part through the triggering of Fc receptors (FcRs) and activation of the complement system [5]. 
In the early 1960s, the existence of circulating antibodies in neonates (cord blood) and healthy 
adults in the absence of exogenous antigen stimulation or deliberate immunization, referred to as 
natural antibodies (nAbs), was also identified [6]. Although the origin and function of nAbs have 
been the subject of age-old discussions, one hallmark of nAbs is that they can be found in germ- 
and antigen-free mice, observations which suggest that their production may be driven, at least in 
part, by self-antigens. However, it is also clear that exposure to microorganisms, either 
intentionally or environmentally derived, results in long-lasting effects on the clonal diversity of 
these Abs, their circulating levels, and ultimately their biological functions which include first 
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line defense as well as immunoregulatory activities.  Here we review several topics on nAbs 
features and functions, and therapeutic applications in human diseases. 
Source and origin of natural antibodies 
Emerging information in mice: Despite the continued interest in nAbs since 1960s, the evidence 
for their cellular source began to emerge only after 1983, particularly in mice. A subset of B 
cells, named B-1 cells, was recognized as the source of nAbs. B-1 cells were initially identified 
by their expression of CD5 and were further characterized by surface expression of IgMhigh, 
IgDlow, CD19high, B220low, CD23−, and CD43+, which contrasts with the surface phenotype of 
follicular B2 cells: CD5−, IgMlow, IgDhigh, CD19+, B220+, CD23+, and CD43− (Table. 1). 
Subsequently, an additional population of B-1 cells was identified, which shared the 
characteristics of CD5+ B1 but lacked CD5 expression. These two populations of B-1 cells are 
termed B-1a (CD5+) and B-1b (CD5−) cells [7, 8].  B-1 cells are found in various tissues of adult 
mice, including the peritoneal cavity, pleural cavity, spleen, bone marrow, lymph nodes and 
blood that contribute to greater than 90% of nAb [7]. Interestingly, B-1 cells located in the 
peritoneal cavity and pleural cavity serve as an important reservoir for B-1a cells and form a pool 
of long-lived, self-renewing B cells that produce most of the circulating natural IgM antibodies 
[9]. However, it has been suggested that within the B-1 cell population, those residing in the 
bone marrow and the spleen are the true nAb-secreting cells, whereas body cavity B-1 cells 
constitute a population of responder (memory type) lymphocytes, which after stimulation 
migrate and differentiate into IgM-secreting cells [8, 10]. In addition, a population of CD138+ B-
1a cells and marginal zone B cells, subset of B-2 cells, are also found to produce nAbs in mice. 
Therefore, more than one B cell population is responsible for nAb production and not all subsets 
of B-1 cells spontaneously secrete nAbs that accumulate in serum, as some of the B-1 cells can 
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differentiate into antigen-induced antibody secreting cells (Table.1) [7]. It should be noted that, 
although B-cell receptor (BCR)-signaling is critical for B-1 cell development, BCR- and T cell-
independent innate immune activation of B-1 cells in body cavities and marginal zone B cells 
(both referred to as innate-like B cells) can induce nAb production.  These stimuli include IL-5, 
IL-10, toll-like receptor (TLR) agonists or whole bacteria that can alter the B-1 cell normal 
trafficking patterns and induce differentiation into cells that secrete large amounts of IgM and/or 
IgA. Furthermore, similar to phenotypic diversity, B-1 cells are also capable of differentiating 
into antigen-induced Ab-secreting cells [7]. Thus, the generalized concept of B-1 cells as 
source/producers of nAbs may not be a complete description. Nevertheless, extensive research 
points to the possibility that, at least in mice, nAbs can originate from multiple B cell subsets that 
arise at different times of development from a distinct progenitor cells [11]. Future studies 
should lead us to an understanding of the role of different source and origin (B cell subsets and 
their stimuli) of nAbs and its contribution to the nAb pool.   
Evidence in humans: In line with mice, nAb secreting cells in humans were first identified as 
CD5+ peripheral B cells [12]. However, CD5−CD45RAlo peripheral B cells were also found to 
produce natural IgM [8, 13]. Further, expression of surface CD5 on cord blood B cells is not a 
definitive marker of an auto/polyreactive population, and also CD5 may be an activation marker 
on human B cells. Notably, recent efforts based on natural/spontaneous antibody secretion 
refined the phenotypic characteristics of nAb-producing cells in human adult and cord blood as 
CD20+CD27+CD43+CD70−CD38mod, the majority of which express CD5 and this is in contrast to 
the phenotype of plasmablasts: CD20−CD27highCD38high (immune Ab-secreting cells) and 
activated memory B cells: CD20+CD27+CD43+CD70+ (Table.1) [14, 15]. Interestingly, similar to 
mice, not all human B-1 cells spontaneously secrete nAbs, and polyclonal stimulation, like TLR9 
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ligand, CpG, increased the frequencies of antibody-secreting cells, a feature also seen in memory 
B cells [15] and transitional B cells [16].  Nevertheless, the phenotype of nAb-secreting cells in 
humans is still unclear, and further studies are required to clarify the specific types of cells 
capable of producing nAbs and also their locations other than in blood. 
Characteristics and reactivity of natural antibodies 
Classes of nAbs and generation in mice and humans: Natural antibodies in the circulation of 
normal healthy individual can be of IgM, IgG and IgA classes. However, studies in mice suggest 
that nAbs are mainly IgM, but also IgA, IgG3 and IgE types, and are proposed to be T-cell 
independent. Although nAbs are mainly germline-like in mice as evidenced by absence of non-
templated nucleotides (N-additions during VDJ recombination) with minimum to no somatic 
hypermutation in VDJ of B-1a cells [17], nAbs with significantly more N-additions and 
hypermutations with isotype switching (IgM to IgG) are seen with increasing age [18]. 
Accordingly, IgG and IgA are also part of the nAb pool in mice, although, unlike serum natural 
IgM, their levels are dependent on exogenous antigen stimulation as evidenced by decreased 
amounts in germ-free mice [8].  Interestingly, unlike mice, IgM is not the only isotype present in 
the prenatal repertoire of human B cells. It was demonstrated that after 26 weeks of gestation, B 
cell clones encoding IgG start to appear in a frequency similar to a frequency observed in healthy 
infants [19]. Therefore, contrary to observations in mice, the nAb pool in humans contains IgM, 
IgG and IgA classes and exhibit similar reactivity in cord blood to that of adults. Furthermore, 
both fetal and adult derived human B cells express Ig with numerous N-additions in VDJ [8], and 
somatic hypermutations occur during human fetal B cell development even in a T cell-
independent fashion [19]. However, there is no evidence in humans for T-cell dependency of 
nAb production, despite the presence of autoreactive T cells in healthy individuals, although 
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mainly with regulatory roles [20]. Autoreactive CD4+ T cells specific for a number of self-
antigens, including myelin basic protein, the acetylcholine receptor, the thyroglobulin-
stimulating hormone receptor and the gpIIbIIIa platelet antigen have been reported in healthy 
individuals. It has been also hypothesized that natural autoreactive B cells are endowed with 
some switching ability in the absence of cognate interactions with T cells, based on the finding 
of small amounts of IgG in the serum of CD40L-deficient patients with the hyper-IgM syndrome 
[21]. Thus, the mechanisms of generation of natural IgM, IgG and IgA antibodies are poorly 
understood and may differ from each other.  
Characteristics of nAbs: In general, nAbs are characterized by their low affinity, high avidity 
and broad/multi reactivity against self-antigens (nAAbs), but some have the ability to recognize 
evolutionarily conserved epitopes occurring in foreign antigens (Figure. 1). In mice, prenatal B-1 
cells express a mainly germ line–encoded repertoire, while postnatally developing B-1 cells can 
express Ig with a greater degree of variation [7]. Yet, the probability of nAb recognition of 
foreign structures as a result of cross-reactivity against self-antigens is still a hotly debated topic. 
However, it is being increasingly appreciated that nAAb production does not represent non-
specific, antigen-independent 'leakage' of terminal B-cell differentiation, but the result of positive 
selection processes for autoreactive B cells dependent on the variable (V) region, resulting in low 
affinity reactivity directed at a set of evolutionarily conserved (auto)antigens, such as circulating 
antigens, cell surface and intracellular structures [20, 22]. These epitopes may exist 
constitutively or represent neoepitopes that result from altered glycosylation of host proteins or 
oxidation of host constituents. Targeting of these endogenous epitopes, which are usually 
sequestered from immunosurveillance, provides beneficial housekeeping functions [23]. 
Therefore, nAAbs are considered to be a manifestation of physiological autoreactivity expressed 
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in healthy individuals, and represent normal responses to self-antigens [20]. In line with this, it 
has been estimated that 5–15% of splenic B-cells activated in vivo can secrete nAbs [21] and up 
to 20% of circulating human B-cells are autoreactive [24]. 
Reactivities of nAbs: Notably, the well-characterized epitopes for nAbs to date are shared by 
pathogens and host, which include phospholipids, oxidized lipids, glycolipids, and glycoproteins, 
both in mice and humans. The best characterized B-1 cell-derived nAb binds the phospholipid 
phosphorylcholine (PC) and utilizes VHS107.1 [25]. PC is found within the bacterial cell wall of 
Streptococcus pneumoniae and is also exposed on apoptotic cells and oxidized lipids, but hidden 
in healthy cells [26]. Studies in mice revealed nAb binding to red blood cells treated with 
bromelain (that exposes phosphatidylcholine, PtC) were B-1 cell derived and utilized VH11, 
VH12 and Q52 [8]. Antibodies that recognize glycan epitopes are also highly abundant in both 
mice and humans. Glycan epitopes are observed on both glycoproteins and glycolipids and can 
be present in autologous or pathogen-associated exogenous structures. In mice, the specificities 
of such antibodies include α-1,3-glucan, N-acetyl-d-glucosamine, and α-1,3-galactose epitopes 
[27]. In humans, the best known anti-glycan antibodies react with blood group antigens A and B, 
the xenoantigen Gal-alpha-1, 3Gal-beta-1,4GlcNAc, Forssman glycolipid antigen, and 
gangliosides such as the tumor-associated antigen Neu5GcGM3 [8, 23]. 
Broad reactivity or polyreactivity of nAbs toward self and/or foreign antigens does not correlate 
with their connectivity (i.e., their ability to interact with variable regions of other autoantibodies) 
[Reviewed in [28]]. Polyreactivity does not suggest lack of specificity, but nAbs are 
“polyreactive” only in the sense that they bind the identical epitope on a variety of molecular 
entities and also feature their own distinct set of epitopic specificities. The notion that an 
antibody must be of high affinity in order to be biologically relevant originates primarily from 
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the analysis of the requirements for an efficient immune response against pathogens. This 
concept does not necessarily apply to natural antibodies. Accordingly, earlier literature suggested 
that nAbs might exhibit a broad range of affinities, with dissociation constants ranging between 
10-5 and 10-8 M. However, advanced technologies to measure protein–protein interactions have 
shown that overall affinity of natural IgG autoantibodies specific for molecules such as HLA 
class I, CD4, the RGD (Arg-Gly-Asp tripeptide) motive and autologous blood group antigens, in 
the micromolar range [21]. 
The germ-line neonatal B-cell repertoire encoding IgM antibodies in the fetus has been 
evolutionarily selected for its reactivity with self-antigens. Interestingly, the self-reactive 
repertoire of IgG is established within the first 2–4 years of life and it is highly homogenous 
among children and similar to that expressed by the IgG of healthy young and older adults, 
whereas the repertoire of IgG (cross)-reactivities toward foreign and self-antigens is diverse and 
dependent on the history of each individual’s immune system [Reviewed in [28]]. Therefore, it is 
now becoming clear that exposure to microorganisms, either intentionally or environmentally 
derived, results in long-lasting effects on the clonal diversity of these Abs, their circulating 
levels, and ultimately their biological functions which include first line defense as well as 
immunoregulatory activities [23]. 
Functions of natural antibodies 
Several lines of evidence have clarified the evolutionarily conserved (cross-)reactivity of nAbs 
supporting an important physiological role in immune system [20], and hence multiple functions 
of nAbs have been postulated. Owing to its cross-reactivity to foreign antigens, nAbs neutralize 
microbes and microbial toxins, strongly suggesting a role for nAbs in natural host defense 
against infection. A major role for nAbs is in immune regulation, which include the removal of 
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senescent/altered self-molecules, cells, and tumors, and controlling untoward autoimmune 
responses, possibly by virtue of their ability to modify the functions of some of their target 
antigens. Indeed, it has been shown that antibodies from healthy individuals display a 
promiscuous hydrolytic activity, as opposed to more specific enzymatic activity of antigen-
specific autoantibodies in patients with autoimmune diseases [Reviewed in [29]].  
Natural antibodies as a first-line of defense against pathogens 
The most relevant roles for infectious disease control are the ability of nAbs to provide 
protection against pathogens, and in the clearance of endotoxin. The first indication of the crucial 
role of nAbs in controlling infections came from the evidence that primary Ig-deficient patients 
display high susceptibility for recurrent infections from bacteria, virus, fungi, and parasites. In 
particular, nAbs have been shown to provide protection against Streptococcus pneumoniae,  
Borrelia hermsii, influenza virus, Listeria monocytogenes, vesicular stomatitis virus, lymphocytic 
choriomeningitis virus, Cryptococcus neoformans, Pneumocystis murina, and Francisella 
tularensis [Reviewed in [8]. Such protection is afforded by virtue of nAbs’ cross-reactivity 
towards ubiquitous bacterial antigens/epitope recognition. For example, in mice, nAbs to 
phosphocholine can protect against intravenous infection with type 3 Streptococcus pneumoniae 
[30].  
Studies using mice and human sera antibodies suggest that anti-microbial nAbs are mainly of 
IgM isotype (Figure. 2), and act by virtue of the ability of polyclonal nIgM to directly recognize 
a wide range of Pathogen Associated Molecular Patterns (PAMPs) that leads to inhibition of the 
growth of microbial pathogens through their direct neutralization, by activation of the classical 
complement pathway to inhibit bacterial growth by lysis, generation of anaphylatoxin C5a, 
enhancement of phagocytosis, neutralization of the functional activity of endotoxin, and 
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amplification of humoral immune responses, leading to the enhanced phagocytosis of these 
opsonized pathogens [31–33]. Mice deficient in natural IgM might be less resistant to viral 
infection or also succumb to infections as a result of a lack of pathogen clearance, decreased 
neutrophil recruitment, and elevated proinflammatory serum cytokines [32, 34].  
In addition, nAbs also alert and prime the adaptive immune system against subsequent pathogen 
attack and are essential in the induction of an immune response that protects against bacterial and 
viral pathogens. The IgG response to T-cell dependent antigens was impaired in IgM-deficit 
mice, which can be rescued by administration of normal IgM prior to immunization [35]. For 
example, lack of natural anti-influenza IgM leads to delayed T-cell-dependent IgG2a response 
and increased mortality in mice [36]. Several mechanisms may be involved in this function of 
nAbs. The formation of immune complexes by nAbs can direct Ags to the secondary lymphoid 
organs, where presentation to T and B-cells is efficient. nAbs may guide the ensuing functional 
polarization of T cell responses, as well the isotype class-switch recombination of the induced B 
cell response and the induction of long-term immune memory. IgM immune complexes with 
pathogens bind complement that in turn binds to complement receptors on DCs and B-cells [34, 
37]. It is known that crosslinking the complement receptor2 (CR2) reduces the triggering 
threshold of B-cells. By allowing simultaneous engagement of BCR and the CD21/CD19, nAbs 
may therefore lower the threshold of B-cell activation. Furthermore, virus/nAb complexes with 
increasing particle size enhance phagocytosis by macrophages in a CR3- and CR4-dependent 
fashion, which can now present virus-derived peptides to T-cells. Finally, polymeric IgM nAbs 
can crosslink the BCR on B-cells that have already captured antigen (Figure. 2)  [Reviewed in 
[28]].  
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Interestingly, in contrast to the direct recognition of microbes by nIgM, recent in vitro studies 
have revealed that natural IgG purified from uninfected/healthy human serum recognized a range 
of gram-negative (eg. Pseudomonas aeruginosa) and gram-positive (eg. Staphylococcus aureus) 
bacteria with the aid of serum lectin innate receptors (e.g., ficolin and Mannan-binding lectin, 
MBL), which are known to bind to sugar residues (e.g., N-acetylglucosamine) on the microbes. 
The partnership between natural IgG and lectins (prebound on the microbe) efficiently drive 
phagocytosis of the bacteria via the FcγR1 receptor on human monocytes [38]. Furthermore, the 
interaction between natural IgG (CH2-CH3 domain on Fc) with ficolin (P-subdomain of FBG 
domain) can be triggered under infection–inflammation conditions to augment the immune 
response [39].  
As previously discussed, exposure to microorganisms that have antigenic epitopes similar to that 
of self-antigens, influences the clonal diversity of nAbs. It is proposed that neonatal exposure to 
conserved epitopes (host and bacterial cells and other common environmental allergens) 
reprograms the natural antibody repertoire directed toward these antigens by clonal expansion, 
alterations in clonal dominance, and increased serum antibody levels. For example, the 
production of nAbs to N-acetyl-D-glucosamine (GlcNAc) shared with bacterial polysaccharide 
(PS) substantially increases in humans with neonatal infection of pneumococcus or group A 
streptococcus (GAS) levels. This has been demonstrated to provide protection against diverse 
pathogenic organisms that may be relevant to the development of allergic diseases. The proposed 
mechanisms of neonatal microbial exposure-induced protection against allergic airway 
inflammation is by engaging epitopes common to multiple allergens, including GlcNac (chitin), 
PC, and glucans, and this leads to interruption of microorganism–innate receptor interactions, 
which can result in an attenuated allergic airway response to fungi-, house dust mite-, and 
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cockroach-associated allergens as seen in mouse models. Here, nAbs may abrogate the 
recognition of these moieties with innate receptors, which recognize the allergens and promote 
immune activation that results in sensitization [23]. However, significant protection against 
airway sensitization is dependent on the timing of induction and the antigenic targets of these 
Abs. The similarities between the murine and human natural antibody repertoires suggest that 
reduced microbial exposure in children may have the opposite effect, providing a potential 
mechanistic explanation for the hygiene hypothesis. In line with this, it is suggested that 
understanding the effects of childhood infections on the natural antibody repertoire and the 
mechanisms of antibody-mediated immune regulation observed in allergy models will lead to the 
development of prevention/interventional strategies for treatment of allergic asthma [23]. 
In further support for the role of nAbs in protection against infections, the therapeutic 
preparation of polyclonal immunoglobulins, intravenous immunoglobulin (IVIG), rich in nAbs is 
commonly used for antibody replacement therapy in primary and secondary immunodeficiency 
patients [40]. Routinely, IVIG (400 mg/kg) is used in patients with X-linked 
agammaglobulinaemia (XLA), common variable immunodeficiency (CVID), X-linked hyper-
IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and selective IgG class 
deficiencies (Table. 2) [40]. Variations in the processing of IVIG products and the geographical 
location of plasma donors might influence the efficacy of IVIG in immunodeficiency [41]. 
Interestingly, several lines of experimental and clinical evidence gathered in recent years reveal 
that therapeutic benefits of IVIG therapy extend beyond the mere anti-infective mechanisms via 
passive transfer of antibodies into the active role of immune homeostasis even in 
immunodeficiency [29, 40, 42–45]. 
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Natural antibodies in tissue homeostasis and immune tolerance 
nAbs may have first arisen to reinforce an important goal of maintaining homeostasis. In line 
with this, as noted previously, the repertoire of nAbs is dominated by self-reactive ones (nAAbs) 
and contributes/mediates the immune regulatory functions of nAbs in physiology, and also the 
disease ameliorative effects of therapeutic immunoglobulin (IVIG) in autoimmune and 
inflammatory disorders. Interestingly, antibody immunodeficiencies are also associated with 
autoimmunity and inflammatory conditions, suggestive of a dysregulated immune status, thus 
supporting the role for nAbs in immune tolerance and maintaining tissue homeostasis [46]. 
Natural IgM (nIgM): role of nAbs in apoptosis and immune regulation: Apoptosis is an 
obligatory outcome of development, proliferation, and cell differentiation that continues 
throughout life. Every day, >1011 cells in our body die by apoptosis, and therefore, apoptotic cell 
(AC) clearance is essential for tissue homeostasis. In health, ACs do not pose an immediate 
threat to the host, as there are redundant means mediated by soluble innate immune molecules, 
such as complement C1Q mannose-binding lectin (MBL) and nAbs to ensure rapid and efficient 
cell corpse clearance by macrophages and dendritic cells (DCs) [47]. If efficiency of AC 
clearance is limited, there can be progression to secondary necrosis and the ensuing release of 
nuclear Ags and other components of dying cells (danger-associated molecular patterns, 
DAMPS), which are believed to activate pattern-recognition receptors (PRRs) of innate immune 
cells that include TLR, leading to inflammatory responses. Necrotic cells can also release 
autoantigens that can select pathogenic B and T cell clones, which together can lead to the 
development of autoimmune disease in predisposed individuals [47, 48]. 
Newborn humans and naïve mice have considerable levels of nIgM that recognize AC 
membranes (ACMs), whereas even higher levels can be induced by intravenous infusions of 
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large numbers of ACs [49, 50]. Furthermore, experimental models have shown that suppression 
of inflammatory arthritis mediated by ACs may require nIgM that can directly inhibit 
macrophage and DC activation [49] and may also promote IL-10–secreting B and T cells [51]. It 
is observed that these effects are facilitated mainly by nAbs to the oxidation-associated 
phosphorylcholine (PC) and malondialdehyde (MDA) neodeterminants on ACMs, which can 
distinguish healthy versus apoptotic cells [50]. Therefore, nIgM directed against PC and MDA 
can have two major regulatory functions, enhanced clearance of ACs by phagocytes (termed 
efferocytosis); and direct suppression of proinflammatory responses induced by agonists for 
TLR3, TLR4, TLR7, and TLR9 and likely many other innate pathways [49, 50]. In consensus 
with murine studies, observations in patients with systemic lupus erythematosus highlighted the 
association of nIgM levels in protection against autoimmunity. For example, decreased levels of 
anti-PC IgM Abs are characteristic features of active lupus compared with the disease in 
remission [52]. Therefore nIgM, through clearance of apoptotic cells, may serve as regulators of 
the innate immune system to help maintain homeostasis and, in certain cases, suppress the 
development of inflammatory and autoimmune diseases [Reviewed in [53]]. 
Furthermore, nIgM is also implicated in suppression of disease-associated IgG autoantibody 
production, since insufficiency of serum IgM may predispose humans for the development of 
IgG autoantibodies [54]. It has also been argued that the protective effect of IgM may at times 
involve anti-idiotypic (i.e., targeting of the Ag receptors of some clonally related lymphocytes) 
downregulation of some autoimmune responses or result from the induction by some IgM anti-
idiotypic Abs of apoptotic death of pathogenic B cell clones or the selection of other protective B 
cell subsets. Another important role of nIgM in tissue homeostasis implicates clearance of altered 
or malignant cells via complement-dependent cell lysis and induction of apoptosis [55]. The 
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maintenance of tissue homeostasis by nIgM may also involve the enhanced clearance of 
misfolded proteins, which could have clinical implications for conditions like Alzheimer’s 
disease in which pathogenesis results from the deposition of misfolded proteins such as β-
amyloid plaques in the brain (Figure. 2) [Reviewed in [53]].  
Normal human plasma contains a substantial amount of nIgM, An IgM-enriched Ig preparation, 
Pentaglobin® that contains 12% IgM has been successfully used for treating infections 
associated with sepsis in patients, as well as transplant rejection, and for certain inflammatory 
conditions in experimental models [53, 56]. Such preparations may also provide benefits to 
combat infections that arise in patients with autoimmune disease [57]. Interestingly, a natural 
human mAb, IgM22 that binds to oligodendrocytes and promotes their remyelination was 
recently tested in human clinical trial, and has demonstrated safe profiles [53]. 
Natural IgG (nIgG): role of nAbs in immune tolerance/homeostasis: As mentioned previously, 
in addition to nIgM, IgG also constitute a major portion of nAbs (as nAAbs). There is little 
information on direct demonstration of the functions of nAbs in immune homeostasis. However, 
most of the functions that have been attributed to IgG nAbs are deduced from the wide range of 
observed effects of IVIG when administered to patients with autoimmune and inflammatory 
situations [29, 58]. IVIG symbolizes a complete repertoire of normal circulating IgG. The 
distribution of IgG subclasses and IgG glycosylation patterns in IVIG generally overlaps with 
normal human plasma/serum. Although a single donor might lack certain individual IgG 
specificities, it is likely to be compensated in IVIG because of pooling of plasma. As IVIG is 
nothing but pooled IgG from normal donors, the effect of IVIG likely represents a primordial 
function of circulating nIgG in regulating immune homeostasis [59]. Natural antibodies and 
natural autoantibodies with low to medium affinity are likely to be the major active components 
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of IVIG, but these specificities are not in high frequencies. Thus, given the altered physiology in 
autoimmune patients, it is conceivable that these natural autoantibodies are needed at higher 
amounts than those present in the normal circulation of a donor. 
IVIG is prepared from pools of plasma obtained from several thousand healthy blood donors, 
and hence IVIG represents a privileged source of nAbs (nAAbs) [60]. Although initially 
conceived for the IgG replacement therapy of primary and secondary immunodeficiencies, 
following successful use of IVIG in immune thrombocytopenic purpura (ITP) by Paul Imbach 
[61], high-dose IVIG (1–2 g/kg) is now used for the immunotherapy of many autoimmune and 
inflammatory diseases  including Guillain–Barré syndrome, Kawasaki disease, myositis, immune 
thrombocytopenic purpura, chronic inflammatory demyelinating polyradiculoneuropathy, and 
many others [42, 62, 63]. Newer indications are continuously being explored, and IVIG is 
currently used in more than 100 different diseases in an off-label manner (Table. 2) [42, 58, 64]. 
As discussed below, numerous mutually non-exclusive mechanisms may play role in the 
beneficial effect of IVIG therapy in these diseases. The success of IVIG in these wide-range 
pathologies provides strong arguments for the therapeutic value of nIgG. 
The effective immunotherapy of autoimmune and inflammatory diseases using IVIG also led to 
the investigation of cellular and molecular mechanisms of action [65]. Autoimmune and 
inflammatory diseases are characterized by abnormal activation of the cells of innate and 
adaptive immune compartments and release of inflammatory mediators. The emerging evidence 
suggests that IVIG targets various arms of the immune system, culminating in inhibition of 
inflammatory cells and soluble mediators while reciprocally enhancing immune regulatory cells 
and their functions. Several mechanisms of action for IVIG have been proposed since its first 
successful therapeutic use in ITP [3]. It was thought initially that IVIG exerts a beneficial effect 
 18 
in autoimmune disease patients via saturation/blockade of Fc receptors on phagocytes such as 
monocytes and macrophages and reduces the immune complex-mediated activation of these 
innate cells [59, 66]. In addition, saturation of FcRn (neonatal Fc receptor), a protective receptor 
that prevents the catabolism of IgG, by IVIG is implicated in accelerated clearance of pathogenic 
antibodies and has a role at least in the initial phase of ameliorative effects of IVIG [65, 67]. 
IVIG has also been shown to neutralize pathogenic autoantibodies by anti-idiotypic Abs against 
idiotypes expressed by disease-associated autoantibodies (to factor VIII, acetylcholine receptor, 
thyroglobulin, DNA and others) and by inhibiting autoantibody production by binding to 
autoreactive B lymphocytes [59, 65, 68]. Further, binding of IVIG to C3b and C4b fragments of 
complement, thereby inhibiting their tissue deposition as well as generation of the C5 convertase, 
and hampering the subsequent formation of C5-C9 membrane attack complex, as a consequence, 
prevents complement-mediated cell death and tissue damage. Additionally, IVIG neutralizes C3a 
and C5a anaphylatoxins via a F(ab′)2-mediated mechanism [62, 69]. IVIG also contains an array 
of anti-cytokine antibodies against various inflammatory cytokines, including granulocyte-
macrophage colony-stimulating factor (GM-CSF), B-cell activating factor (BAFF) that can 
dampen inflammatory process [59, 70, 71]. 
Interestingly, F(ab’)2 and Fc portions of IVIG can inhibit lymphocyte (B and T cells) 
proliferative responses and modulate inflammatory cytokines [63, 72, 73]. In addition, IVIG can 
also induce apoptosis of mononuclear cells implicating death receptor Fas [74], 
polymorphonuclear cells via Siglec [75], and also conversely block of Fas in toxic epidermal 
necrolysis to inhibit apoptosis [76]. IVIG also normalizes the functions of DCs and other innate 
immune cells [43, 77, 78]. Further, IVIG induces expansion of regulatory T cells (Tregs) and 
reciprocally inhibits Th17 cells [79, 80, 89, 81–88]. Interestingly, recent studies in mouse models 
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suggest that α-(2, 6) sialylated Fc of IVIG signals through type II lectin receptors to enhance 
inhibitory FcγRIIB on effector macrophages via basophil-secreted IL-4 and induce Tregs by 
dendritic cell-specific intercellular adhesion mol-ecule-3-grabbing nonintegrin (DC-SIGN)-
induced IL-33 secretion [90, 91]. However, translation of these findings to humans failed to 
recapitulate the mechanisms although requirement of sialylation has been confirmed in other 
experimental models [78, 79, 82, 83, 88, 89, 92]. Studies in humans have revealed that IVIG can 
directly interact with basophils to induce IL-4 secretion, and can act either directly on Tregs or 
on DCs to expand Tregs [46, 65, 93–96]. 
In summary, IVIG can interfere at all steps of immune response from the early initiation phase to 
the later effector phase that leads to clinical disease (Figure. 3). Accordingly, binding of nAAbs 
to antigens contributes to their internalization by antigen-presenting cells and thus modulates the 
processing of antigens and their subsequent presentation to T cells. Of particular interest for the 
dissection of the effects of IVIG in autoimmune diseases, is the role of nAAbs in the inhibition 
of soluble mediators of inflammation (including complements and cytokines), maintenance of 
cellular homeostasis, in preventing the expansion of specific autoreactive clones of T and B cells, 
and in the ability of nAAbs to regulate self-reactivity (pathogenic autoantibodies). Thus, the 
mechanisms of action of IVIG are complex and unlike other specific antibody-based therapies 
that are either in clinic or in development [97-102], a single mechanism might not account for its 
therapeutic benefit in autoimmune diseases [42, 65, 103]. 
In line with the immune modulatory effects of IgG and IgM nAbs, other subclasses of normal 
Igs, particularly IgA, have been explored. Preclinical evaluation of pooled IgA (analogous to 
IVIG) provided evidence that normal IgA also ameliorates inflammation and hence demands 
further clinical evaluation [104, 105]. 
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Conclusions 
Natural antibodies are distinct from pathogenic-specific immune antibodies and pathologic 
autoantibodies (Table. 3). Notably, nAbs can exert immune modulatory function as evidenced by 
activating as well as inhibitory effects based on the host immune status (immunodeficiency 
versus inflammatory). This phenomenon is similar to the diverse effects of B cells (source of 
Abs/nAbs) on different immune cells, e.g. DCs, depending on the activation stimuli [106-110]. 
More than half of the nascent B cells in humans initially express autoreactive antibodies. 
However, most of these autoantibodies are removed from the repertoire at two checkpoints 
before maturation into naive B cells. A third checkpoint excludes remaining autoantibodies from 
the antigen-experienced IgM+ and IgG+ memory B cell pool [111, 112]. Nevertheless, low-
affinity self-reactive antibodies of all classes IgM, IgG and IgA are frequently found in the serum 
of normal individuals. However, little attention has been paid to their role in immune responses 
or how their production can be manipulated to the host’s advantage [113, 114]. The inordinate 
focus on the dogma that high affinity IgG response is the goal of immunization and that so-called 
sticky, low-affinity Abs should be avoided is the primary reason for this dearth of information. 
Recent investigations in the field should lead to more focus on the functions of this first-line 
component of the adaptive immune response.  
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Figure Legends 
Figure. 1. Natural antibodies and pathogen-specific immune antibodies. In addition to 
immune antibodies that develop following active exposure to pathogen-derived antigens through 
infection or immunization, our immune system also produces natural antibodies (nAbs) that are 
constitutively expressed in the absence of external antigens. Further, unlike the monoreactivity of 
immune antibodies, nAbs are predominantly polyreactive capable of binding many structurally 
unrelated antigens with similar affinity.  
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Figure. 2. Natural IgM in immune tolerance and homeostasis. nIgM can sustain immune 
equilibrium by acting as a first line of defense against invading pathogens, shaping the anti-
microbial response, and by regulating the immune tolerance and homeostasis. nIgM confer 
protection against pathogens through direct neutralization, activation of the classical complement 
pathway, opsonization of pathogens and their phagocytosis by innate cells like dendritic cells 
(DC) and macrophages (MΦ), and transportation of antigens to secondary lymphoid organs for 
initiating the immune responses. In addition, nIgM can also shape the immune response to 
pathogens by regulating the T cell polarization and B cell class-switch. The role of nIgM in 
immune homeostasis involves recognition and clearance of apoptotic cells, altered cells and 
misfolded proteins, and regulation of disease-associated B cell clones and IgG antibodies. B, B 
cell; C1Q, complement C1Q (classical complement pathway); T, T cell. The figure is reproduced 
with modifications by permission from The Journal of Immunology, The American Association 
of Immunologists, Inc [53]. 
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Figure. 3. The mechanisms of action of IVIG on various arms of autoimmune and 
inflammatory responses. The autoantigens endocytosed by the innate immune cells such as 
dendritic cells and macrophages are presented to the self-reactive T and B cells leading to the 
proliferation of autoreactive cells, production of inflammatory cytokines and autoreactive 
antibodies. IVIG targets different soluble and cellular compartments of the immune system to 
exert its therapeutic effects on diverse autoimmune diseases. IVIG neutralizes autoantigens and 
superantigens, and inhibits the activation of diverse innate immune cells such as dendritic cells, 
macrophages, monocytes, granulocytes and NK cells. Concerning the effector phase of 
autoimmune response, IVIG inhibits the activation and proliferation of effector T (Th1, Th17) 
and B cells while enhancing the expansion and function of regulatory T cells (Tregs). IVIG also 
induces expression of inhibitory FcγRIIB in a subset of macrophages and B cells. Further, IVIG 
saturates the neonatal Fc receptors (FcRn), modulates the cytokine network, induces apoptosis of 
immune cells, neutralizes pathogenic autoantibodies by anti-idiotypic interaction, inhibits the 
activation of complements and regulates the B cell repertoire. Abbreviations: ADCC, antibody-
dependent cell-mediated cytotoxicity; FcγR, Fcγ receptors; NK, natural killer cell. 
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Table. 1. Cellular source of natural antibodies (nAbs) in mice and humans 
 Mice Human 
Property B1a B1b MZ B2 FO B2 B1-like B2-like 
Cell surface 
phenotype 
IgMhigh, IgDlow, 
CD19high, B220low, 
CD23−, CD43+, 
CD138+/-, CD5+ 
IgMhigh, IgDlow, 
CD19high, B220low, 
CD23−, CD43+, 
CD138+/-, CD5− 
IgMhigh, IgDlow, 
CD19mid, CD21high, 
CD23−, CD43−, 
CD5− 
IgMlow, IgDhigh, 
CD19high, B220+, 
CD23+, CD43− 
and CD5− 
CD20+, CD27+, 
CD43+, CD70−, 
CD38mod, 
CD45RAlow, CD5-/+ 
CD20+, CD27+, 
CD43+, CD70+, 
CD38mod 
Development 
Positive selection on 
self-antigen 
Unclear pathway 
Selection of weak 
self-reactive 
Selection for non-
self-reactive 
usually 
Positive selection on 
self-antigen 
Usually 
selection for 
non-self-reactive  
Tissue distribution 
Peritoneal cavity, pleural cavity, 
spleen, bone marrow, lymph nodes and blood 
Spleen Spleen 
Blood, other 
locations? 
Blood, lymph 
nodes and 
spleen 
Self-renewing B1 
cells 
Mainly B1 cells from body cavities, but adult 
bone marrow as precursor 
N/A N/A Yes N/A 
Spontaneous 
nAb secretion 
Mainly B1 cells from spleen and bone marrow 
for IgM; and Intestinal mucosa and lung 
parenchyma for IgA 
Nil N/A Yes Nil 
Induced 
nAb secretion 
Mainly B1 cells from peritoneal cavity after CpG, LPS for IgM; and 
Intestinal mucosa and lung parenchyma for IgA 
N/A Yes 
stimulus  
differentiated 
cells 
Stimulus for 
response 
BCR-independent, but 
need innate receptor or 
cytokine signals 
BCR-dependent 
expansion 
BCR-dependent 
expansion 
BCR-dependent 
expansion 
BCR-independent, 
and need innate 
receptor or cytokine 
signals 
BCR-dependent 
expansion 
Contribution to 
circulating nAbs 
Mainly B1 cells from spleen and bone marrow for IgM; and 
Intestinal mucosa and lung parenchyma for IgA 
N/A unknown N/A 
N/A: Not applicable 
 2 
Table 2.  Therapeutic utility of IVIG in immunodeficiency, and autoimmune and inflammatory pathologies 
Licensed FDA/EMA* Off-label 
•  Primary immunodeficiencies  
[Eg. X-linked agammaglobulinemia (XLA),  
Common variable immunodeficiency (CVID) 
 
• Secondary immunodeficiencies  
[Eg. B-cell  chronic lymphocytic leukemia (CLL), 
Paediatric HIV infection] 
 
• Idiopathic thrombocytopenic purpuraa 
• Kawasaki Disease a 
• Chronic inflammatory demyelinating polyneuropathy a 
• Guillain–Barré syndromea # 
• Multifocal motor neuropathya 
• Bone marrow transplantation 
 
• Myasthenia Gravisa 
• Autoimmune hemolytic anemia  
• Acquired immune thrombocytopenias 
• Juvenile idiopathic arthritis 
• Anti-phospholipid antibody syndrome 
• Lambert–Eaton syndrome 
• Dermatomyositisa 
• Parvovirus B19-associated red cell aplasia  
• Anti-factor VIII autoimmune disease  
• Acquired von Willebrand disease 
• Autoimmune neutropenia 
• Steroid-dependent severe atopic dermatitis 
• Stiff person syndrome 
• Toxic epidermal necrolysis  
• Polymyositis 
• Multiple sclerosis 
• Rheumatoid arthritis and Felty’s syndrome 
• Systemic lupus erythematosus  
• Autoimmune skin blistering diseases a 
• Antibody-mediated rejection of the graft 
• Graft versus host diseasea 
• Autoimmune uveitis and birdshot chorioretinopathy 
• Streptococcal or staphylococcal sepsis and toxic shock syndrome  
• ANCA-positive systemic vasculitis 
• Graves ophthalmopathy 
a Indicates pathologies for which evidence for the clinical benefits of IVG has been obtained through controlled clinical trials.  
* Licensed for use by US FDA and EMA, # Approved by European Medical agency (EMA) only 
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Table 3. Comparison of natural antibodies, immune antibodies and pathogenic autoantibodies 
 
Feature Pathogen-specific immune antibodies  
Natural Antibodies (nAbs) 
Pathogenic autoantibodies 
Pathogen cross-reactive  Self-reactive   
Develops following Infection or immunization Constitutive/Homeostasis Constitutive/Homeostasis Uncontrolled autoimmunity 
 
Influence of external 
antigen on clonal 
diversity 
 
Yes 
 
Yes 
 
No 
 
Yes? 
 
Source/Cells 
    
Mouse B2*, also B1* B1 mainly B1 mainly B2 mainly 
Human CD20-CD27highCD38high CD20+CD27+CD43+CD70−CD38mod CD20+CD27+CD43+CD70−CD38mod CD20-CD27highCD38high 
 
Somatic 
hypermutation  
 
Present 
 
Nil to minimum 
 
Nil to minimum 
 
Present 
 
Isotypes 
 
IgG mainly, also IgA, IgM, IgE 
 
IgM mainly, also IgG and IgA 
 
IgM and IgG, also IgA 
 
IgG mainly, also IgM and IgA 
 
T-cell dependence 
for induction 
 
Yes 
 
Nil to minimum 
 
Nil to minimum 
 
Yes 
 
 
Affinity 
 
Usually High 
 
Low 
 
Low 
 
High 
 
Avidity 
 
High 
 
High 
 
High 
 
High 
 
Reactivity 
 
Pathogen epitope specific 
 
 
Self, cross-reactive to conserved 
epitopes  
 
Polyreactive to self-antigens 
 
Specific self-antigen 
 
Examples of antigens 
 
Influenza Hemagglutinin 
 
Phosphorylcholine (PC)  
 
HLA class I, CD4 
 
Citrullinated protein antigens 
 
Functional outcome 
 
 
Prevention and control of pathogen-
induced disease 
 
Prevention of pathogen infection 
 
 
Beneficial housekeeping tissue 
homeostasis functions 
 
 
Inflammation and tissue 
destruction leading to disease 
 
*B1: IgMhigh, IgDlow, CD19high, B220low, CD23−, and CD43+; CD5+ (B1a) or CD5- (B1b) 
*B2: IgMlow, IgDhigh, CD19high, B220+, CD23+, and CD43- 
